USA flag logo/image

An Official Website of the United States Government

Prescription Drug Abuse Screening and Pain Management Plan Training Simulation

Award Information

Department of Health and Human Services
Award ID:
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
9861 BROKEN LAND PKWY, STE 200 COLUMBIA, MD 21046-3039
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 2
Fiscal Year: 2010
Title: Prescription Drug Abuse Screening and Pain Management Plan Training Simulation
Agency: HHS
Contract: 2R44DA026229-02
Award Amount: $781,740.00


DESCRIPTION (provided by applicant): Prescription drug abuse is a growing concern for several reasons. The practice of obtaining multiple prescriptions and early refills poses a number of health risks for patients who use prescription drugs; because multip le prescriptions or early refills are not closely monitored, it is sometimes up to the primary care physician to properly screen for signs of potential prescription drug abuse and addiction. Clinicians in primary care settings should be equipped with the k nowledge to recognize the signs of potential abuse, as well as the steps necessary to address patients who are deemed to be addicted to, or abusing, prescription drugs. The interaction can be difficult, because many patients are either unaware of or evasiv e about their addiction or abuse. Providing simulation training to help prepare clinicians to better screen patients for potential prescription drug abuse and to identify treatment methods to help these high-risk patients deal with their chronic pain would be very effective. For the Phase II application, SIMmersion LLC, in cooperation with Dr. Michael Fleming of the University of Wisconsin, proposes to develop and evaluate a full-featured interactive simulation to train clinicians in primary care settings h ow to screen for prescription drug misuse and apply pain management plans. The proposed training simulation will allow physicians and other primary healthcare practitioners to practice the detection and management of prescription opioid misuse in patients suffering from chronic pain. The ideal outcome would be that clinicians become more proficient and comfortable with these skills, and therefore more likely to use them as a routine part of their practice with all patients, thereby reducing the number of pe ople being harmed by the misuse of prescription drugs. To evaluate the efficacy of the simulation training system, Dr. Fleming and his research team will conduct an educational trial. One hundred students and practitioners will be randomly assigned to usua l education on prescription drug abuse and misuse (n=50) or to the SIMmersion training program (n=50). Subjects will complete baseline and 6-month post-measures of knowledge and clinical behavior. The measures will include a knowledge pencil-and-paper test and standardized patients. The research will be conducted at the UW Health Sciences Clinical Teaching and Assessment Center. The simulated patient program, using the SIMmersion technology, is expected to significantly advance our ability to train medical professionals in human processing and interaction skills. We expect the end result of the SBIR grant will include improved skills among healthcare professionals in prescription drug screening and application of pain management plans, as well as improved pa tient outcomes for those who use prescription drugs to manage chronic pain. PUBLIC HEALTH RELEVANCE: Innovative and economical technologies that assist primary care clinicians in acquiring competence in screening patients for prescription drug abu se and chronic pain management could help increase the frequency and efficacy of screening for potential abuse. Screening patients for prescription drug abuse in primary care settings and implementing treatment management plans may help identify abuse soon er and lead to life-changing interventions, which could reduce the negative impact of prescription and other drug abuse and addiction.

Principal Investigator:

Dale E. Olsen

Business Contact:

Laura Boteler
Small Business Information at Submission:


EIN/Tax ID: 161142311
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No